Search Results

You are looking at 71 - 80 of 193 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

-consistent/NCCN-nonconsistent trials involved adjuvant endocrine therapy; 2 used a gonadotropin-releasing hormone (GnRH) agonist and tamoxifen in premenopausal women, and 4 used tamoxifen in postmenopausal women. A GnRH agonist with tamoxifen is included in the AGO guidelines for

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

possible advantage of SERMs compared with estrogen therapy is the lack of early increase in coronary heart disease and a significant reduction in hormone receptor-positive breast cancer. Results of the ongoing STAR trial (Study of Tamoxifen and Raloxifene

Full access

predictor of breast cancer outcomes; however, several emerging biomarkers, such as the CYP 2D6 genotype to determine tamoxifen (Soltamox, AstraZeneca Pharmaceuticals, LP) efficacy, are also being researched extensively. “The efficacy of tamoxifen therapy

Full access

Robert Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Craig D. Blinderman, Barry Boston, Charles Cleeland, Nessa Coyle, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Nora A. Janjan, Sloan Beth Karver, Michael H. Levy, Maureen Lynch, Natalie Moryl, Barbara A. Murphy, Suzanne A. Nesbit, Linda Oakes, Eugenie A. Obbens, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan Urba, and Sharon M. Weinstein

hepatic enzyme, CYP2D6. 29 , 30 Because data suggest that CYP2D6-inhibiting antidepressants increase risk of recurrence in patients with breast cancer treated with tamoxifen 31 , 32 (see Additional Therapies, page 1082), it is reasonable to assume that

Full access

William J. Gradishar

to the group of patients who had not been exposed to adjuvant tamoxifen. Dr. Gradishar questioned whether this outcome was clinically relevant. He stated that even though the SWOG trial may support administering combination therapy in first

Full access

Linda Overholser and Carlin Callaway

.2019) recommend that women taking tamoxifen for invasive breast cancer should have an annual gynecologic assessment every 12 months. However, recommendations from the American College of Obstetricians and Gynecologists (ACOG) do not align with those from NCCN for

Full access

Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias, and Peter Kabos

studies was based on the SWOG-8814 randomized clinical trial, the results of which were published in 2009 and showed that adjuvant treatment including both chemotherapy and tamoxifen yielded a longer survival benefit over tamoxifen alone in hormone

Full access

Kenneth Offit

advised. An example of a guideline based on risk threshold can be drawn from the Tamoxifen prevention trial that used a 1.67% 5-year risk of developing breast cancer for a 60-year-old woman enrolled in the trial. 6 Population-based mammogram screening

Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith

Mouridsen H Gershanovich M Sun Y . Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group . J Clin Oncol

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass, and Nicole R. McMillian

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship define menopause as no menses for 1 year in the absence of prior chemotherapy or tamoxifen use, or no menses after surgical removal of all ovarian tissue. Healthy women